Why did GLMD's EPS remain flat in Q3 2023?

Galmed Pharmaceuticals (GLMD) experienced a flat EPS in Q3 2023 due to a combination of factors:

1. **Strategic Expansion**: Galmed has been expanding its clinical development strategy into new anti-fibrotic indications. This strategic move might have necessitated maintaining a certain level of expenditure, which could have flattened the EPS.
2. **Prior Year's Performance**: Comparing the current year's EPS with the previous year's EPS is essential. If the EPS was higher in the previous year, the current year's flat EPS might not be a cause for concern if it was a high point.
3. **Market Conditions**: The broader market conditions, including competition and market demand, can influence a company's financial performance. If the market is challenging, it might impact Galmed's revenue and, consequently, its EPS.

In conclusion, Galmed's flat EPS in Q3 2023 can be attributed to a combination of strategic expansion and market conditions.